Causes of hair loss and the developments in hair rejuvenation

International Journal of Cosmetic Science

Volumn 24, Issue 1, 2002, Pages 17-23

  Rushton, D Hugh ^a   Norris, M J ^b   Dover, R ^b   Busuttil, Nina ^b  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b 24 Harmont House ^*  (United Kingdom)

Author keywords

Androgenetic alopecia; Chronic telogen effluvium; Common balding; Finasteride; Florisene ; Hair loss; Hair shedding; Hair treatments; Male pattern balding; Propecia ; Regaine

Indexed keywords

CYPROTERONE ACETATE; ESTROGEN; FERRITIN; FINASTERIDE; LYSINE; MINOXIDIL; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; FERRITIN BLOOD LEVEL; GENETIC PREDISPOSITION; HAIR GROWTH; HAIR LOSS; HUMAN; IRON DEPLETION; MALE TYPE ALOPECIA; NUTRITIONAL STATUS; PATHOLOGY; REJUVENATION; TREATMENT OUTCOME;

EID: 0036425173     PISSN: 01425463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0412-5463.2001.00110.x     Document Type: Article

References (27)

1. Kingsley, D.H. The Development and Validation of a Quality of Life Measure for the Impact of Androgen-dependent Alopecia. PhD Thesis, University of Portsmouth, Portsmouth (1999).
2. Cash, T.F. The psychology of physicalappearance. Aesthetics, attributes, and images. In: Body Images: Development, Deviance and Change (T. F. Cash and T. Pruzinsky, eds), pp. 51-79. New York: Guilford Press (1990).
3. Cash, T.F. The psychological effects of androgenetic alopecia in men. J. Am. Acad. Dermatol. 26, 926-931 (1992).
4. Giacometti, L. Facts legends and myths about the scalp throughout history. Arch. Dermatol. 95, 629-631 (1967).
5. Hamilton, J.B. Patterned loss of hair in man: Types and incidence. Ann. NY Acad. Sci. 53, 708-728 (1951).
6. Norwood, O.T. Male pattern baldness: Classification and incidence. Southern Med. J. 68, 1359-1370 (1975).
7. Ludwig, E. Classification of the types of androgenic alopecia (common baldness) occurring in the female sex. Br. J. Dermatol. 97, 247-254 (1977).
8. Rushton, D.H., Ramsay, I.D., Norris, M.J. and Gilkes, J.J.H. Natural progression of male pattern baldness in young men. Clin. Exp. Dermatol. 16, 188-192 (1991).
9. Bingham, K.D. and Shaw, D.A. The metabolism of testosterone by human male scalp skin. J. Endocrinol. 57, 111-121 (1973).
10. Schweikert, H.U. and Wilson, J.D. Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J. Clin. Endocrinol. Metab. 38, 811-819 (1974).
11. Harris, G., Azzolina, B., Baginsky, W., et al. Identification and selective inhibition of an isozyme of the steroid 5a-reductase in human scalp. Proc. Natl. Acad. Sci. USA. 89, 10787-10791 (1992).
12. Rushton, D.H., Unger, W.P., Cotterill, E.C., et al. Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness. Clin. Exp. Dermatol. 14, 40-46 (1989).
13. Price, V.H. and Menefee, E. Quantitative estimation of hair growth: Comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. In: Hair Research for the Next Millennium (D. J. Van Neste and V. A. Randall, eds), pp. 67-71. Amsterdam: Elsevier (1996).
14. Kaufman, K. Clinical studies on the effects of oral finasteride, a type II 5α-reductase inhibitor, on scalp hair in men with male pattern baldness. In: Hair Research for the Next Millennium (D.J. Van Neste and V.A. Randall, eds), pp. 363-365. Amsterdam: Elsevier (1996).
15. James, K.C., Norris, M.J., Rushton, D.H., et al. The influence of thyroid dysfunction on hair growth. J. Pharm. Pharmacol. 39, 64 (1987).
16. Courtois, M., Loussouarn, G., Hourseau, C. et al. Ageing and hair cycles. Br. J. Dermatol. 132, 86-93 (1995).
17. Rushton, D.H., James, K.C. and Mortimer, C.H. The unit area trichogram in the assessment of androgen-dependent alopecia. Br. J. Dermatol. 109, 429-437 (1983).
18. Rushton, D.H., Ramsay, I.D., James, K.C. et al. Biochemical and trichological characterisation of diffuse alopecia in women. Br. J. Dermatol. 123, 187-197 (1990).
19. Rushton, D.H. Investigating and managing hair loss in apparently healthy women. Can. J. Dermatol. 5, 455-461 (1993).
20. Roberts, J.L. Examining the etiology of telogen effluvium in pre-and postmenopausal women: A chart review study. Proceedings, Tri-Continental Hair Research Meeting, Tokyo, Japan, Poster 157 (2001).
21. Haycox, C. The incidence of depleted iron stores in North American females presenting with hair loss. Proceedings, Tri-Continental Hair Research Meeting, Tokyo, Japan, Poster 159 (2001).
22. Mortimer, C.H., Rushton, D.H. and James, K.C. Effective medical treatment for common baldness in women. Clin. Exp. Dermatol. 8, 342-350 (1984).
23. Rushton, D.H. and Ramsay. I.D. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin. Endocrinol. 36, 421-427 (1992).
24. Rushton, D.H., Futterweit, W., Kingsley, D.H., Kingsley, P. and Norris, M.J. Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia. J. Soc. Cosmet. Chem. 42, 317-325 (1991).
25. Rushton, D.H. and Fenton, D.A. Quantitative evaluation of topical 5% minoxidil in the treatment of diffuse androgen-dependent alopecia in females. Br. J. Dermatol. 127, 423 (1992).
26. Whiting, D.A., Waldstreicher J., Sanchez, M. and Kaufman, K.D. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. J. Invest. Dermatol. Symp. Proc. 4, 282-284 (1999).
27. Puolakka, J. Serum ferritin the evaluation of iron status in young women. Acta. Obstet. Oynecol. Scand. Suppl. 95, 35-41 (1980).